CoChat

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

Open access
Cochaud, Stéphanie, Giustiniani, Jérôme, Thomas, Clémence, Laprevotte, Emilie, Garbar, Christian, Savoye, Aude-Marie, Curé, Hervé, Mascaux, Corinne, Alberici, Gilles, Bonnefoy, Nathalie, Eliaou, Jean-François, Bensussan, Armand, Bastid, Jeremy · 2013 · Scientific Reports
Cited by 156

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The proinflammatory cytokine Interleukin 17A (hereafter named IL-17A) or IL-17A producing cells are elevated in breast tumors environment and correlate with poor prognosis. Increased IL-17A is associated with ER(-) or triple negative tumors and reduced Disease Free Survival. However, the pathophysiological role of IL-17A in breast cancer remains unclear although several studies suggested its involvement in cancer cell dissemination. Here we demonstrated that a subset of breast tumors is infiltrated with IL-17A-producing cells. Increased IL-17A seems mainly associated to ER(-) and triple negative/basal-like tumors. Isolation of tumor infiltrating T lymphocytes (TILs) from breast cancer biopsies revealed that these cells secreted significant amounts of IL-17A. We further established that recombinant IL-17A recruits the MAPK pathway by upregulating phosphorylated ERK1/2 in human breast cancer cell lines thereby promoting proliferation and resistance to conventional chemotherapeutic agents such as docetaxel. We also confirmed here that recombinant IL-17A stimulates migration and invasion of breast cancer cells as previously reported. Importantly, TILs also induced tumor cell proliferation, chemoresistance and migration and treatment with IL-17A-neutralizing antibodies abrogated these effects. Altogether these results demonstrated the pathophysiological role of IL-17A-producing cell infiltrate in a subset of breast cancers. Therefore, IL-17A appears as potential therapeutic target for breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep03456

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 156

Metadata

Authors
Cochaud, S., Giustiniani, J., Thomas, C., Laprevotte, E., Garbar, C., Savoye, A.-M., Curé, H., Mascaux, C., Alberici, G., Bonnefoy, N., Eliaou, J.-F., Bensussan, A., & Bastid, J.
Venue
Scientific Reports
Published
2013-12-09
Volume
3
Issue
1
Pages
3456-3456
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2140374399
Cited by
156
References
5
FWCI
2.28
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. https://app.cochat.ai/papers/10.1038/srep03456
The paper
Cochaud, S., Giustiniani, J., Thomas, C., Laprevotte, E., Garbar, C., Savoye, A.-M., Curé, H., Mascaux, C., Alberici, G., Bonnefoy, N., Eliaou, J.-F., Bensussan, A., & Bastid, J. (2013). IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Scientific Reports. https://doi.org/10.1038/srep03456

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.